Janssen Pharmaceutica NV /
LianBio Development (HK) Limited
Janssen Pharmaceutica NV to acquire rights from LianBio Development (HK) Limited
What happened
LianBio Development and its affiliates agreed to sell rights in licensed products and related assets to Janssen Pharmaceutica NV. The transaction was effective as of Dec. 22, 2023.
The licensed products include NBTXR3, an investigational potential first-in-class radioenhancer.
The source
Everything on this page comes from the source below.
Janssen Pharmaceutica NV to acquire rights from LianBio Development (HK) Limited
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly